Thyroid Cancer Clinical Trial
Official title:
To Evaluate the Practicable, Thoroughness and Clinical Value of Bilateral Central Compartment Dissection While Preserve Contrary Thyroid Glands
NCT number | NCT03454464 |
Other study ID # | CCD |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | January 1, 2018 |
Est. completion date | December 31, 2018 |
In accordance with the current guidelines,papillary thyroid microcarcinoma such as turmo invasive nerve or trachea, requires total thyroidectomy for follow-up iodine-131 treatment.In the course of clinical work, if the patient can achieve R0 resection, most of the patients do not need iodine-131 treatment,Therefore, there is no need to continue total thyroidectomy.To evaluate the practicable, thoroughness and Clinical value of bilateral central compartment dissection while preserve contrary thyroid glands.
Status | Recruiting |
Enrollment | 100 |
Est. completion date | December 31, 2018 |
Est. primary completion date | December 31, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: Tumor diameter less than 1cm The tumor is located in the lower part of the gland No lateral cervical lymph node metastases Traditional open surgery Exclusion Criteria: Select the endoscopic surgery or robotic surgery patients Tumor invades the surrounding trachea and esophagus Patients refused to participate |
Country | Name | City | State |
---|---|---|---|
China | Wen-xin ZHAO | Fuzhou | Fujian |
Lead Sponsor | Collaborator |
---|---|
Fujian Medical University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | number of the lymph node | the number of the lymph node | 2 day post operation | |
Primary | number of postive lymph node | The number of postive lymph node | 2 day post operation | |
Primary | The weight of the central compartment tissue. | The weight of the central compartment tissue. | introoperation | |
Secondary | thyroid volume | thyroid volume | The day before the operation | |
Secondary | recurrent laryngeal nerve palsy | the number of recurrent laryngeal nerve palsy | 1 day ,2weeks,3months,6months post operation |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05774535 -
Prospective, Observational Study on the Carotid Intima-media Thickness in Patients Undergoing Thyroid Surgery
|
||
Withdrawn |
NCT04224792 -
Effects of Exercise Training on Fatigue in Thyroid Cancer Survivors
|
N/A | |
Completed |
NCT01728623 -
A Study of E7080 in Subjects With Advanced Thyroid Cancer
|
Phase 2 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT02911155 -
Cancer and Other Disease Risks in U.S. Nuclear Medicine Technologists
|
||
Recruiting |
NCT05025046 -
NGS-based Thyroscan Genomic Classifier in the Diagnosis of Thyroid Nodules
|
||
Not yet recruiting |
NCT03978351 -
The Role of Midkine in Diagnosis of Thyroid Cancer
|
||
Completed |
NCT02658513 -
Evaluation of Lancet Blood Sampling for Radioiodine Dosimetry in Thyroid Cancer
|
||
Terminated |
NCT02628535 -
Safety Study of MGD009 in B7-H3-expressing Tumors
|
Phase 1 | |
Completed |
NCT02375451 -
Effect of Childhood Radioiodine Therapy on Salivary Function
|
N/A | |
Withdrawn |
NCT01994200 -
Developing and Implementing an Interdisciplinary Team-Based Care Approach (ITCA-ThyCa) for Thyroid Cancer Patients
|
Phase 1/Phase 2 | |
Terminated |
NCT01403324 -
Comparison of Dosimetry After rhTSH or Withdrawal of Thyroid Hormone in Metastatic or Locally Advanced Thyroid Cancer
|
N/A | |
Completed |
NCT00970359 -
Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244
|
N/A | |
Completed |
NCT00439478 -
Dental Safety Profile of High-Dose Radioiodine Therapy
|
Phase 4 | |
Completed |
NCT00223158 -
Evaluation Study of L-T3 Utility in the Follow-up of Patients With Thyroid Cancer
|
N/A | |
Active, not recruiting |
NCT04544111 -
PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
|
Phase 2 | |
Completed |
NCT04876287 -
Salivary dysfuncTion After Radioiodine Treatment
|
||
Recruiting |
NCT06073223 -
Intervention to Decrease Overtreatment of Patients With Low-risk Thyroid Cancer
|
N/A | |
Recruiting |
NCT06037174 -
Comparison of Quality of Life in Patients With Differentiated Thyroid Carcinoma Undergoing Different Surgery
|
||
Recruiting |
NCT04952493 -
Anlotinib or Penpulimab in Combination With RAI for DTC
|
Phase 2 |